MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug.  The new buy zone is $32 to $35.57.  Recommended position size is 35% to 40%.  The stock is trading at $38.40 as of this writing.

What To Do Now

Those in the stock may continue to hold.

Those not in the stock may consider waiting for a dip into the buy zone.